- Home
- XAIR vs MRKR Comparison
XAIR vs MRKR Comparison
Compare XAIR & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- MRKR
- Stock Information
- Founded
- XAIR 2011
- MRKR N/A
- Country
- XAIR United States
- MRKR United States
- Employees
- XAIR N/A
- MRKR N/A
- Industry
- XAIR Medical/Dental Instruments
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- MRKR Health Care
- Exchange
- XAIR Nasdaq
- MRKR Nasdaq
- Market Cap
- XAIR 17.0M
- MRKR 19.1M
- IPO Year
- XAIR N/A
- MRKR N/A
- Fundamental
- Price
- XAIR $0.17
- MRKR $1.71
- Analyst Decision
- XAIR Strong Buy
- MRKR Strong Buy
- Analyst Count
- XAIR 2
- MRKR 3
- Target Price
- XAIR $1.50
- MRKR $13.17
- AVG Volume (30 Days)
- XAIR 5.4M
- MRKR 102.6K
- Earning Date
- XAIR 08-05-2025
- MRKR 08-13-2025
- Dividend Yield
- XAIR N/A
- MRKR N/A
- EPS Growth
- XAIR N/A
- MRKR N/A
- EPS
- XAIR N/A
- MRKR N/A
- Revenue
- XAIR $3,705,000.00
- MRKR $5,696,123.00
- Revenue This Year
- XAIR $286.75
- MRKR N/A
- Revenue Next Year
- XAIR $144.39
- MRKR $11.28
- P/E Ratio
- XAIR N/A
- MRKR N/A
- Revenue Growth
- XAIR 219.67
- MRKR 71.53
- 52 Week Low
- XAIR $0.15
- MRKR $0.95
- 52 Week High
- XAIR $0.68
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- XAIR 45.07
- MRKR 60.22
- Support Level
- XAIR $0.15
- MRKR $1.56
- Resistance Level
- XAIR $0.29
- MRKR $1.93
- Average True Range (ATR)
- XAIR 0.02
- MRKR 0.10
- MACD
- XAIR 0.00
- MRKR 0.02
- Stochastic Oscillator
- XAIR 29.86
- MRKR 57.69
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.